0.307
0.07 (29.43%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - General (US) | 看涨 | 看涨 |
| Drug Manufacturers - General (全球的) | 看涨 | 看涨 | |
| 股票 | Scilex Holding Company | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.75 |
|
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - General |
| 投资方式 | Small Core |
| 内部持股比例 | 25.93% |
| 机构持股比例 | 20.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Murchinson Ltd. | 31 Dec 2024 | 663,705 |
| Rafferty Asset Management, Llc | 31 Dec 2024 | 620,131 |
| 52周波幅 | ||
| 中 | 18.00 (5,755.56%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 02 Apr 2025 | 18.00 (5,755.56%) | 购买 | 0.316 |
| 28 Feb 2025 | 22.00 (7,056.80%) | 购买 | 0.236 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合